Recursion Pharmaceuticals Q4 2023 GAAP EPS $(0.42) Beats $(0.44) Estimate, Sales $10.89M Miss $20.35M Estimate
Portfolio Pulse from Benzinga Newsdesk
Recursion Pharmaceuticals (NASDAQ:RXRX) reported Q4 2023 earnings with a smaller-than-expected loss per share of $(0.42) versus the $(0.44) estimate, but missed revenue expectations with $10.89M against a $20.35M estimate. Year-over-year, the loss per share increased by 35.48% and revenue decreased by 20.36%.
February 27, 2024 | 9:37 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Recursion Pharmaceuticals reported a Q4 2023 EPS of $(0.42), beating estimates, but missed on revenue with $10.89M against a $20.35M forecast. Losses and revenue declines were noted year-over-year.
The mixed earnings report from Recursion Pharmaceuticals, with an EPS beat but a significant miss on revenue expectations, is likely to have a negative short-term impact on the stock. The worsening of losses and decline in revenue year-over-year further contribute to a bearish outlook in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100